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Identity 
Other names: MGC12685; PCGF4; RNF51;flvi-
2/bmi-1 





Local order: MLLT10 gene is one of the neighboring 
genes of BMI1. It locates 786566 base  
pairs downstream from the start site of BMI1. MLLT10 
or AF10 is a transcription factor which is also one of 
the fusion proteins of ALL. ALL-AF10 can result in the 
development of T-cell ALL, AML FAB 0, AML FAB 
1, AML FAB 5 and AML FAB 7. PIP4K2A is the gene 
for Phosphatidylinositol-4-phosphate 5-kinase. The 
protein transcribed from this gene is catalyzing the 
phosphorylation of phosphatidylinositol-5-phosphate 
on the fourth hydroxyl of the myo-inositol ring to form 
phosphatidylinositol-5,4-bisphosphate. 
Phosphatidylinositol-5,4-bisphosphate is a precursor to 
second messengers in the phosphoinositide signal trans-
duction pathways and it is involved in the regulation of 
secretion, cell proliferation, differentiation and motility. 
DNA/RNA 
Description 
DNA size: 10.04 kb with 10 exons. 
The BMI1 gene is a highly conserved gene. The cDNA 
shows 86% identity to the mouse sequence. 
Transcription 
mRNA size: 3199 bp. 
Protein 
Note 
326 amino acids 
Molecular weight of the protein: 36949 Da. 
 










The ring finger domain is a cysteine-rich domain that 
binds two atoms of zinc and plays a key role in the 
process of ubiquitination. In hematopoietic stem cells 
BMI1 interacts with a proliferation inhibitor E4F 
through the IE4F site. 
Expression 
Hematopoietic system: BMI1 is expressed in adult 
and embryonic fetal liver hematopoietic stem cells 
(HSC). During hematopoietic development the 
expression of BMI1 declines. Bmi1-/- mice are born 
with a hypocellular bone marrow, they have normal 
number of myeloid cells in the peripheral blood but 
lower number of lymphocytes. In the bone marrow of 
Bmi1-/- mice the total HSC number is decreased with 
10-fold and transplanted bone marrow and fetal liver 
cells were able to contribute to hematopoiesis only 
transiently. Bmi1-depleted mice die within two months 
after birth. Adult HSCs from Bmi1-/- mice lack self-
renewal potential. Further-more, expression of stem 
cell-associated genes, cell survival genes, transcription 
factors and genes modulating proliferation was altered 
in the bone marrow cells. BMI1 overexpression was 
studied in transgenic mice and human CB models. In 
these mouse models 14% of the mice developed 
lymphoma. BMI1 overexpression in CD34+ cord blood 
cells resulted in long term maintenance and self-
renewal of human hematopoietic stem and progenitor 
cells. These cells engrafted more efficiently in NOD-
SCID mice and gave a rise to secondary engraftment. 
Nervous system: BMI1 is required for neural stem cell 
self-renewal but it does not influence their survival and 
differentiation. BMI1 is strongly expressed in 
proliferating cerebellar precursor cells in mice and 
humans. The absence of BMI1 was related to the low 
level of p16 Ink4 as well as to low proliferation rate of 
neural stem cells. BMI1-deficient mice develop balance 
disorders, tremor, behavior disorders and they have a 
severe reduction in total postnatal brain mass. 
Fibroblasts: In BMI1-deficient primary mouse 
embryonic fibroblast cell cycle progression to S phase 
was impaired and cells entered early senescence. 
Localisation 
In nucleus and in the cytoplasm. 
Function 
BMI1 is a member of the Polycomb group (PcG) genes, 
which are transcriptional repressors that play essential 
roles in the maintenance of appropriate gene expression 
during development. Two distinct multiprotein PcG 
complexes have been identified, the Polycomb 
Repression Complex (PRC) 1 and PRC2. The PRC2 
complex is involved in initiation of silencing and 
contains histone deacetylases and methyltransferases 
that can methylate H3 lysine 9 and 27 (H3K27). 
Deletion of PRC2 genes in mice results in embryonic 
lethality, emphasizing their importance in development. 
PRC1 is implicated in stable maintenance of gene 
repression and recog-nizes the methylation marks set 
by PRC2. Mice mutant for most PRC1 genes survive 
until birth as result of partial functional redundancy 
provided by their homologues, but developmental 
defects do arise thereafter as is e.g. the case in the 
hemato-poietic compartment after deletion of BMI1. 
Targeted deletion of BMI1 has shown that although the 
numbers of fetal liver-derived HSCs is normal in these 
mice, their proliferative and self-renewal capacity is 
severely impaired. In adult BMI1-deficient mice, the 
HSCs are less frequent and display an impaired 
competitive repopulation capacity. Gain-of-function 
studies demonstrated enhanced self-renewal of murine 
HSC and with a shift in balance towards more 
symmetric stem cell divisions. Constitutive expression 
of BMI1 in human cord blood cells results in prolonged 
maintenance of the stem cell pool and enhances self-
renewal of human stem and progenitor cells. BMI1 is 
potent negative regulator of the Ink4a/Arf locus in 
embryonic fibroblasts. This locus encodes the cell cycle 
regulators and tumor suppressor p16 and p19/p14.  
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Increased expression of these genes was observed in 
the BMI1-deficient mice. However, INK4A/ARF-
independent BMI1-targets must exist as well since 
overexpression of BMI1 in p16/p19-deficient cells still 
altered HSC self-renewal phenotypes. 
Mutations 
Note 
A mutation in BMI1 that results in a cysteine into 
tyrosine substitution at position 18 within the RING 
domain has been identified, which is associated  





BMI1 overexpression has been demonstrated in several 
hematological malignancies, mainly including mantle 
cell lymphoma, myeloid dysplastic syndrome (MDS), 
chronic myeloid leukemia (CML) and acute myeloid 
leukemia (AML). 
Prognosis 
In general, high BMI1 expression levels are associated 
with a poor prognosis and increased aggressiveness of 
the tumors. In CML, the level of BMI1 at diagnosis 
correlated with time to transfor-mation to blast crisis. 
In MDS, patients with RA and RARS with a higher 
percentage of BMI1-positive cells showed disease 
progression to RAEB. Intriguingly, in CML post allo-
SCT, high BMI1 at diagnosis predicts better overall 
survival, which might be ascribed to the neutralized 
effects against BMI1 by an immune response in donor 
cells. 
Cytogenetics 
Different chromosomal translocations involving the 
10p11-13 region have also been identified in infant 
leukemias, occurring in children < 12 months of age 
and T cell lymphoproliferative disorders, including 
mainly adult T cell leukemia/lymphomas and 
occasional cutaneous T cell lymphomas. It was 
demonstrated that BMI1 was overexpressed with 
MEIS1 in 11q23 (MLL) rearrangements, suggesting 






BMI1 overexpression was implicated in various solid 
tumors, including ovarian cancer, bladder cancer, 
squamous cell carcinoma, prostate cancer, breast 




The oncogenic role of the BMI1 activation may 
contribute to progression of many types of solid 
tumors. The median survival is 46 months and 5-year 
survival is 37.5% in BMI1/EZH2-positive prostate 
cancer patients after radical prostatectomy (The 5-year  
survival is 72.4% in BMI1/EZH2-negative prostate 
cancer patients). But in breast cancer, increased BMI1 
expression is associated with a good prognosis, which 
might be because BMI1 overexpression correlates with 
higher ER expression and lower TP53 mutations. 
Oncogenesis 
See below. 
Neural stem cells renewal 
Note 
BMI1 promotes the maintenance of adult neural stem 
cells (NSCs) by repressing the cyclin-depen-dent 
kinase inhibitors, p16Ink4a and p19ARF. Recent study 
showed that BMI1 was also important for NSCs in the 
embryo, using lentiviral-delivered shRNAs in vitro and 
in vivo. These defects caused by BMI1 downregulation 
were unexpectedly mediated by p21. 
Oncogenesis 
Gene-profiling studies show that BMI-/- HSC displayed 
altered expression of multiple genes important for stem 
cell fate decisions. The tumor suppressor locus 
p16Ink4a/p19ARF is one of the important targets that is 
repressed by BMI1. The p16Ink4a protein blocks the 
cyclinD-CDK complexes by binding directly to CDK4 
and CDK6, enabling CIP1 and KIP1 to associate with 
and inhibit cyclin E-CDK2 and cyclin A-CDK2, which 
results the hypophosphorylated pRb. The E2F 
transcription factors will be sequestered and their target 
genes will be repressed, ultimately leading to G1-phase 
cell cycle arrest, senescence, or apoptosis. p19ARF binds 
to MDM2 and inhibits its ubiquitin ligase activity, 
resulting in activation of p53 target genes, including 
Wig1 and p21, leading to cell cycle arrest and 
apoptosis. Furthermore, cells might undergo apoptosis 
as a result of down-regulated apoptosis inhibitor AI-6 
in the absence of BMI1. BMI1 was also demonstrated 
to upregulate the human telomerase RT gene (hTERT), 
which might also be relevant for the self-renewal 
ability of HSCs or LSCs. 
Deregulated Hox gene expression caused by 
chromosomal translocations and MLL rearrange-ments, 
is involved in some types of leukemia. The skeletal 
defects of PcG mutant mice revealed PcG genes as Hox 
gene regulators. Knockout of BMI1 results in 
alterations in Hox gene expression, with 12 Hox genes 
significantly upregulated (for example, HoxA7-
HoxA13; HoxC10-HoxC13) and 13 downregulated (for 
example, HoxA1-HoxA4). This study demonstrated 
that BMI1 and RING1A play important roles in H2A 
ubiquitylation and Hox gene silencing. 
 






Atlas Genet Cytogenet Oncol Haematol. 2010; 14(2)  90 
Overexpression of BMI1 is involved in tumor 
development and is used as an important marker for 
predicting prognosis. The mechanisms regulating BMI1 
expression are not fully elucidated yet. In AML, BMI1 
was demonstrated to be a direct target gene of SALL4, 
a zinc-finger transcription factor, which is expressed 
constitutively in human leukemia cell lines and primary  
AML cells. High levels of H3-K4 trimethylation and 
H3-K79 dimethylation were observed in the SALL4 
binding region of the BMI1promoter. In normal and 
malignant human mammary stem cells activation of 
hedgehog signaling increases BMI1 expression and 
BMI1 overexpression promotes mammary stem cell 
self-renewal and proliferation. In CML, it was 
suggested that BMI1 was positively regulated by BCR-
ABL as well as by additional posttrans-criptional 
modification in the course of the disease progression. 
Chromatin association and dissociation of BMI1 was 
also studied. BMI1 can be phosphorylated by 3pk 
(MAPKAP kinase 3), a convergence point downstream 
of activated ERK and p38 signaling pathways which 
are implicated in differentiation and developmental 
processes. BMI1 phosphoryla-tion results in 
dissociation of BMI1 from chroma-tin, followed by de-
repression of target genes. 
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